We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Five‐year survival follow‐up of a phase III randomised trial comparing ofatumumab versus physicians' choice for bulky fludarabine‐refractory chronic lymphocytic leukaemia: a short report.
- Authors
Miklos, Udvardy; Strugov, Vladimir; Lewerin, Catharina; Grosicki, Sebastian; Mazur, Grzegorz; Steurer, Michael; Montillo, Marco; Kryachok, Irina; Middeke, Jan M.; Rekhtman, Grygoriy; Stefanelli, Tommaso; Vincent, Ghislaine; Govindaraju, Sameera; Österborg, Anders
- Abstract
Summary: In 2014, an interim analysis of a phase 3 study was performed to evaluate the effectiveness of ofatumumab in patients with bulky fludarabine‐refractory chronic lymphocytic leukaemia (BFR CLL) as compared to physician's choice. The five‐year follow‐up of this phase 3 trial showed that ofatumumab therapy resulted in a numerically but not significantly longer overall survival. As only few patients had the chance to receive a kinase inhibitor later, the study displays the survival of BFR CLL patients in the period prior to receiving small‐molecule inhibitors. Ofatumumab is a well‐tolerable treatment option in multiresistant advanced CLL.
- Subjects
LYMPHOCYTIC leukemia; CHRONIC leukemia; FLUDARABINE; PHYSICIANS; CHRONIC lymphocytic leukemia; KINASE inhibitors
- Publication
British Journal of Haematology, 2020, Vol 189, Issue 4, p689
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.16429